Researchers used AI and molecular docking to screen thousands of natural compounds, narrowing the list to 200 candidates. The top lead reduced injury in human kidney cells exposed to glucose and lipid stress. This hybrid approach accelerates early-stage drug discovery for Cathepsin L targets. It demonstrates a practical pipeline for validating computational hits in vitro.